Filing Flows › Cytokinetics (CYTK) › Q1 2025
Cytokinetics (CYTK) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Cytokinetics (CYTK) reported revenue of $1.6M for the first quarter 2025 (Q1 2025), +89% from a year earlier and -91% from the quarter before.
Cytokinetics, Q1 2025: revenue $1.6M (+89% year over year), net loss $161M, operating cash flow −$132M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -91% | +89% |
| Operating profit | −$156M | — | — |
| Net earnings | −$161M | — | — |
| Operating cash flow | −$132M | — | — |
What changed
Revenue was $1.6M in Q1 2025, up 89% year over year and down 91% from the previous quarter.
Operating costs exceeded revenue by $155.6M, an operating margin of -9856.3%. Total costs grew 24% against revenue growth of 89%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $161.4M, wider than the previous quarter's $150.0M loss.
Operating cash flow was −$131.6M. Non-cash charges added back $2.3M of depreciation and amortization and $23.5M of share-based compensation. Capital expenditures of $5.7M exceeded it, leaving free cash flow of −$137.3M.
Questions
What was Cytokinetics' revenue in the first quarter 2025?
Cytokinetics (CYTK) reported revenue of $1.6M for the first quarter 2025 (Q1 2025), +89% from a year earlier and -91% from the quarter before.
Source: Cytokinetics 10-Q on SEC EDGAR.